Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
作者： G. Folprecht , M. Nowacki , I. Lang , S. Cascinu , I. Shchepotin
DOI: 10.1200/JCO.2009.27.15_SUPPL.4076
关键词: Oncology 、 Colorectal cancer 、 First line 、 Medicine 、 Quality of life 、 FOLFIRI 、 Cetuximab 、 Internal medicine 、 In patient
摘要: 4076 Background: Assessing QoL is important to evaluate the impact of treatment on pts with mCRC. The phase III CRYSTAL trial compared cetuximab plus FOLFIRI alone in first-line tr...
sci-hub.st 参考文章(0)